CIK 0001404281 · Non-accelerated filer<br>Smaller reporting company
Eledon Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ELDN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 949-238-8090
- Business address
- 19800 MACARTHUR BLVD., SUITE 250, IRVINE, CA, 92612
- Former names
- Eledon Pharmaceuticals, Inc., Novus Therapeutics, Inc., Tokai Pharmaceuticals Inc
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2014-09-22 | Harrison Seth Loring Director | Conversion · Series B-1 Preferred Stock | −798,067 | 0 | ||
| 2014-09-22 | Harrison Seth Loring Director | Conversion · Series B-2 Preferred Stock | −644,786 | 0 | ||
| 2014-09-22 | Harrison Seth Loring Director | Conversion · Series C Preferred Stock | −14,604,833 | 0 | ||
| 2014-09-22 | Harrison Seth Loring Director | Conversion · Series D-1 Preferred Stock | −8,711,335 | 0 | ||
| 2014-09-22 | Harrison Seth Loring Director | Conversion · Series D-2 Preferred Stock | −1,539,643 | 0 | ||
| 2014-09-22 | Harrison Seth Loring Director | Conversion · Series D-3 Preferred Stock | −24,046,035 | 0 | ||
| 2014-09-22 | Harrison Seth Loring Director | Conversion · Series E Preferred Stock | −24,199,308 | 0 | ||
| 2014-09-22 | Novartis Bioventures Ltd 10% owner | Conversion | +4,319,328 | 4,319,328 | ||
| 2014-09-22 | Novartis Bioventures Ltd 10% owner | Purchase | +325,000 | $15.00 | $4.9M | 4,644,328 |
| 2014-09-22 | Novartis Bioventures Ltd 10% owner | Conversion · Series D-1 Preferred Stock | −15,396,431 | 0 | ||
| 2014-09-22 | Novartis Bioventures Ltd 10% owner | Conversion · Series D-2 Preferred Stock | −1,539,643 | 0 | ||
| 2014-09-22 | Novartis Bioventures Ltd 10% owner | Conversion · Series D-3 Preferred Stock | −13,222,826 | 0 | ||
| 2014-09-22 | Novartis Bioventures Ltd 10% owner | Conversion · Series E Preferred Stock | −15,064,469 | 0 | ||
| 2014-09-22 | BARBERICH TIMOTHY J Director | Conversion | +121,077 | 121,077 | ||
| 2014-09-22 | BARBERICH TIMOTHY J Director | Conversion · Series D-3 Preferred Stock | −457,731 | 0 | ||
| 2014-09-22 | BARBERICH TIMOTHY J Director | Conversion · Series E Preferred Stock | −809,955 | 0 | ||
| 2014-09-22 | Morrison Jodie Pope President and CEO | Grant or award · Stock Option (right to buy) | +165,251 | 165,251 | ||
| 2014-09-17 | Kalowski Lee Chief Financial Officer | Grant or award | +54,604 | 54,604 | ||
| 2014-09-17 | Kalowski Lee Chief Financial Officer | Grant or award · Stock Option (right to buy) | +218,417 | 218,417 | ||
| 2014-06-15 | Novartis Bioventures Ltd 10% owner | Sale | −14,777 | $14.20 | $210K | 4,546,616 |
Page 15 of 15 · 300 trades